The guidance provides recommendations
to sponsors holding Investigational New Drugs, New Drug
Applications, and Biologics License Applicatons on what
pharmacogenomic data to submit to the Agency during the drug
development process, the format of submissions, and how the data
will be used in regulatory decisionmaking.
US Code:
21
USC 312 Name of Law: Investigational New Drug Apllication
Based on our experience with
the submission of voluntary genomic data submissions under this
guidance over the past few years, the number of annual responses
has been reduced from 7 to 4 because of reduced submissions. There
are no other changes or adjustments.
$462,000
No
No
No
No
No
Uncollected
Ila Mizrachi 301 796-7726
ila.mizrachi@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.